Cantor Fitzgerald lowered the firm’s price target on Elutia to $10 from $11 and keeps an Overweight rating on the shares following the Q2 results. The 2024 story continues to center around the commercial launch of EluPro, as the company is methodically ramping its sales force as it now has 26 representatives on the EluPro team and says it has sufficient manufacturing capacity to scale EluPro, as the VAC approval process remains the rate-limiting step to driving adoption in the near-term, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELUT:
- Elutia to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
- Elutia to Present at the Emerging Growth Conference on Thursday, July 18
- Elutia price target raised to $10 from $5 at Lake Street
- Elutia price target raised to $11 from $5 at Cantor Fitzgerald
- Aziyo Biologics Gains FDA Clearance for EluPro® Bioenvelope